Prognostic indices and therapy in IgA nephropathy: toward a solution.
IgA nephropathy is the primary renal disease with the greatest impact on services. The paucity of trials with high evidence-based standards gives emphasis to issues of the rationalization of therapies. Now that certain treatments are increasingly accepted and others under evaluation, reliable discriminatory tests are essential to define and select patients at high risk of progression before irreversible loss of renal tissue, while avoiding drug exposure in others.
Ballardie
F W
FW
Department of Nephrology and (Internal) Medicine, Manchester Royal Infirmary, Manchester, UK. francis.ballardie@cmmc.nhs.uk
Cowley
R D
RD
D015415:Biomarkers / Q000652:urine; D018932:Chemokine CCL2 / Q000652:urine*; D018450:Disease Progression; D004815:Epidermal Growth Factor / Q000652:urine*; D005922:Glomerulonephritis, IGA / Q000473:pathology / Q000652:urine*; D006801:Humans; D007668:Kidney / Q000473:pathology; D011379:Prognosis
D015415:Biomarkers; D018932:Chemokine CCL2; D004815:Epidermal Growth Factor